Due to the recent shift in metabolic liver disease nomenclature to include cardiometabolic risk factors as diagnostic criteria, we also highlight HuR’s involvement in extrahepatic metabolic tissues, including adipose, cardiac, and immune cells, where its dysregulation contributes to comorbid conditions such as obesity, CVD, and T2DM, all of which exacerbate MASLD. The gene discussed is ELAVL1; the disease is metabolic dysfunction-associated steatotic liver disease.